Rankings / Comparisons
Testosterone (TRT / supraphysiological) vs HGH (recombinant human growth hormone)
The two pillars of the off-label performance corner — anabolic effect, risk profile, and legal exposure compared.
Reviewed by Read Off Label · How we grade
Score comparison
Testosterone (TRT / supraphysiological) has the higher descriptive composite (B, 6.8/10) compared with HGH (recombinant human growth hormone) (C-, 4.2/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
- Evidence
- Strong (muscle, bone, sexual function in hypogonadism); Strong (muscle in eugonadal at supraphysiological doses — Bhasin 1996) (8/10)
- Benefit
- Strong (supraphys); Med (TRT) (8/10)
- Risk
- Med (TRT); High (supraphysiological — erythrocytosis/HCT>54, HPG suppression/infertility, gynecomastia, acne, sleep apnea, prostate/BPH; CV risk NOT increased in TRT per TRAVERSE but unclear at supraphysiological doses) (5/10 safety)
- Legality
- Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal
- Dose / route context
- TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles 300-1000+ mg/week
- Class
- Anabolic
- Last reviewed
- Jun 8, 2026
Read Off Label grades Testosterone (TRT / supraphysiological) as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.
TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury.
Studied, labeled, or reported-use context: TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles… — Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal; not individualized guidance.
What it is
TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury. Reduced progression to diabetes. FDA February 2025 label change: REMOVED boxed warning for major adverse cardiovascular events; ADDED class-wide warning for blood pressure increases (per ambulatory BP monitoring data). Bhasin 1996 NEJM remains definitive demonstration of dose-dependent muscle gain in healthy men. Yeap 2026 J Clin Endocrinol Metab review: nonlinear association of low testosterone with all-cause mortality below ~213 ng/dL.
Mechanism
Prototypical androgen receptor agonist; increases muscle protein synthesis, satellite cell activation, erythropoiesis, bone density; aromatizes to estradiol (necessary for bone, libido, lipids)
Full Testosterone (TRT / supraphysiological) review →
- Evidence
- Weak-Moderate (anti-aging claims — Rudman 1990 reanalyses show muscle gain but no functional benefit, increased side effects); Strong (deficiency indications: pediatric GHD, adult GHD, Turner, wasting) (4.5/10)
- Benefit
- Med (5/10)
- Risk
- Med-High (carpal tunnel, edema, insulin resistance / overt diabetes, arthralgia; tumor growth promotion concern; cardiomegaly at high chronic doses; expensive — $800-1500/month) (3.5/10 safety)
- Legality
- Rx for approved indications; off-label/illicit for anti-aging/performance illegal in US (Anti-Drug Abuse Act of 1988 specifically criminalizes non-indicated HGH)
- Dose / route context
- Clinical: 0.005-0.03 mg/kg/day subQ; anti-aging/illicit: 2-4 IU/day
- Class
- Anabolic
- Last reviewed
- Jun 8, 2026
Read Off Label grades HGH (recombinant human growth hormone) as C- (4.2/10) based on weak-moderate evidence, med benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Rudman 1990 NEJM revived anti-aging interest — but followups show muscle gain with no functional improvement and high side effect burden.
Studied, labeled, or reported-use context: Clinical: 0. — Rx for approved indications; off-label/illicit for anti-aging/performance illegal in US; not individualized guidance.
What it is
Rudman 1990 NEJM revived anti-aging interest — but followups show muscle gain with no functional improvement and high side effect burden. Liu 2007 Annals systematic review: in healthy older adults, HGH increases lean mass modestly but increases adverse events without improving performance. Expensive; counterfeits widespread in illicit market.
Mechanism
Exogenous somatotropin; binds GHR; raises IGF-1; lipolytic; promotes collagen, cartilage, connective tissue; muscle anabolism modest on its own but synergistic with androgens
Full HGH (recombinant human growth hormone) review →
Common questions
- How do the evidence profiles of Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone) compare?
- Testosterone (TRT / supraphysiological) has the higher descriptive composite (B, 6.8/10) compared with HGH (recombinant human growth hormone) (C-, 4.2/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
- What's the difference between Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone)?
- The two pillars of the off-label performance corner — anabolic effect, risk profile, and legal exposure compared.
- Can you take Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone) together?
- The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.
This is an independent synthesis of published research by a non-clinician.
The comparison reports composite and axis-level differences without selecting
an intervention for the reader. Relevance depends on indication, population,
dose, duration, and other context. See the full
disclaimer and methodology.